After baseline assessments, ADHD participants were randomized to receive either Atomoxetine or placebo first. Atomoxetine dose was determined according to participant body mass, as per prescribing guidelines (mean dose was 1.35 mg.kg−1; range 1.0–1.4 mg.kg−1) (Tsang et al., 2011 (link)). Atomoxetine and placebo preparations were purchased from Eli Lilly. Both Atomoxetine and placebo doses were packaged externally into blister packs to maintain double blinding. The Atomoxetine and placebo pill and packaging were identical in appearance. Compliance to treatment was monitored by a daily record booklet completed by parents/guardian and the return of empty blister packs.
Atomoxetine
Manufactured by Eli Lilly
Sourced in United States
Atomoxetine is a chemical compound used for the manufacture of pharmaceutical products. It is a selective norepinephrine reuptake inhibitor (SNRI) that can be used as a component in the production of various medications. The core function of atomoxetine is to serve as a raw material in the development of therapeutic formulations.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using atomoxetine
1
Randomized Trial of Atomoxetine for ADHD
2
ADHD Pharmacotherapy Dosing Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The children received pharmacologic therapy as indicated by the second edition of the Chinese ADHD guidelines, released in 2015 [36 ]. Atomoxetine (Eli Lilly and Company, Indianapolis, IN, USA) was administered orally once daily (d) using an initial dose of 0.5 mg/kg/d. The amount was gradually increased up to a maximum of 1.2 mg/kg/d according to the tolerance of the drug and the improvement of core symptoms. Once symptom control was achieved, the dose was maintained throughout the treatment.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!